ENOrphanet Journal of Rare Diseases | Multicenter Study of Chronic Inflammatory Arthritis in 22q11.2 Deletion Syndrome
Date: April 05, 2025
Classification: Frontiers
Recommend:
This study reviews the clinical features, treatment strategies, and outcomes of 30 patients with 22q11.2 deletion syndrome and chronic inflammatory arthritis, revealing unique clinical characteristics of arthritis in this syndrome, including early onset, polyarticular involvement, elevated inflammatory markers, and negative RF and CCP antibodies. It highlights the potential benefit of early introduction of biologic agents in disease control and suggests that arthritis in 22q11.2 deletion syndrome may represent a distinct disease entity separate from juvenile idiopathic arthritis.
Literature Overview
The article titled 'Chronic inflammatory arthritis in 22q11.2 deletion (DiGeorge) syndrome: a multicenter study' published in the Orphanet Journal of Rare Diseases summarizes clinical manifestations, diagnostic approaches, and treatment strategies of 30 patients diagnosed with 22q11.2 deletion syndrome (22q11DS) and chronic inflammatory arthritis between 1992 and 2024. The study shows a higher proportion of female patients (20 cases), with a median age of arthritis onset at 3 years. Half of the patients presented with polyarticular involvement, and most exhibited elevated inflammatory markers (ESR and CRP), while antinuclear antibody (ANA) was positive in a significant number of cases. RF and CCP antibodies were consistently negative. Treatment included systemic corticosteroids, methotrexate (MTX), and biologic agents. The study suggests that arthritis in 22q11.2 deletion syndrome may represent a distinct clinical entity, different from classical juvenile idiopathic arthritis.Background Knowledge
22q11.2 deletion syndrome (22q11DS) is a genetic disorder caused by the deletion of the 22q11.2 chromosomal region, with an estimated incidence of 1 in 4,000 live births. About 90% of cases are de novo mutations. The syndrome presents with a wide range of phenotypes, including cardiac malformations, craniofacial anomalies, thymic hypoplasia, immune dysfunction, and neurodevelopmental disorders. In recent years, increasing attention has been given to the association between 22q11DS and autoimmune diseases (e.g., arthritis, thyroiditis, vitiligo), although the underlying mechanisms remain unclear. Studies indicate that approximately 77% of 22q11DS patients suffer from immune dysfunction, such as reduced T-cell receptor diversity and impaired regulatory T cell (Treg) function, leading to decreased self-tolerance and increased susceptibility to autoimmune reactions. Juvenile idiopathic arthritis (JIA) is the most common form of chronic arthritis in children, yet the incidence of arthritis in 22q11DS patients is significantly higher than the estimated prevalence in the general population. This study aims to systematically analyze the clinical features, laboratory findings, and treatment responses in patients with 22q11DS and arthritis, to determine whether it represents an independent disease phenotype and to provide evidence for clinical management.
Study Design and Methods
The study employed a multicenter retrospective cohort design, collecting clinical data of patients diagnosed with 22q11.2 deletion syndrome and chronic inflammatory arthritis between 1992 and 2024 through email surveys. Inclusion criteria were patients with genetically confirmed 22q11DS and chronic inflammatory arthritis onset before age 16, lasting more than six weeks. Exclusion criteria included lack of molecular confirmation, failure to meet the definition of chronic arthritis, or presence of another joint disease. Data collected included demographics, clinical features, laboratory findings, treatment approaches, and infection history. Descriptive statistical analyses were performed, including mean, median, range, and frequency analysis.Key Findings and Insights
Research Implications and Future Directions
This study is the first systematic description of the clinical features of arthritis in 22q11DS, indicating it may represent a distinct disease entity different from JIA. Future prospective studies are needed to further explore the underlying immune mechanisms and develop standardized treatment guidelines. Larger sample sizes and control groups (e.g., JIA patients) are required to assess the specificity of arthritis in this syndrome. Long-term follow-up data are also crucial for evaluating the risk of joint damage and functional impairment.
Conclusion
This retrospective analysis of 30 patients with 22q11.2 deletion syndrome and chronic inflammatory arthritis reveals unique clinical features, including early onset, polyarticular involvement, elevated inflammatory markers, negative RF and CCP antibodies, and a low incidence of uveitis. Treatment strategies included systemic corticosteroids, methotrexate, and biologic agents, with over half of the patients receiving biologics. While disease control was generally favorable, over half of the patients still had active arthritis at the last follow-up. Some patients experienced severe infections or malignancies, suggesting that immune dysfunction may increase the risk of infections and cancers. The study suggests that arthritis in 22q11DS may be a rare complication of the syndrome, rather than a mere comorbidity, potentially linked to T-cell dysfunction and reduced immune tolerance. Future large-scale prospective studies are needed to further clarify the pathogenesis and optimize treatment strategies to reduce joint damage and functional impairment.
